Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data
Pancreatic ductal adenocarcinoma (PDAC), already among the deadliest epithelial
malignancies, is rising in both incidence and contribution to overall cancer deaths. Decades …
malignancies, is rising in both incidence and contribution to overall cancer deaths. Decades …
Tumor mutational burden as a potential biomarker for immunotherapy in pancreatic cancer: systematic review and still-open questions
Simple Summary Tumor mutational burden (TMB) represents the number of mutations per
megabase (muts/Mb) harbored by tumor cells in a given neoplasm, and can be determined …
megabase (muts/Mb) harbored by tumor cells in a given neoplasm, and can be determined …
Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma
Purpose: KRAS mutation (MT) is a major oncogenic driver in pancreatic ductal
adenocarcinoma (PDAC). A small subset of PDACs harbor KRAS wild-type (WT). We aim to …
adenocarcinoma (PDAC). A small subset of PDACs harbor KRAS wild-type (WT). We aim to …
The CCTG PA. 7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal …
Immunotherapy-based monotherapy treatment in metastatic pancreatic ductal
adenocarcinoma (mPDAC) has shown limited benefit outside of the mismatch repair …
adenocarcinoma (mPDAC) has shown limited benefit outside of the mismatch repair …
Atlas of PD-L1 for pathologists: indications, scores, diagnostic platforms and reporting systems
Background. Innovative drugs targeting the PD1/PD-L1 axis have opened promising
scenarios in modern cancer therapy. Plenty of assays and scoring systems have been …
scenarios in modern cancer therapy. Plenty of assays and scoring systems have been …
Moving the needle on precision medicine in pancreatic cancer
The management of pancreatic ductal adenocarcinoma (PDAC) has posed a considerable
challenge for decades, with incidence and mortality rates almost mirroring each other …
challenge for decades, with incidence and mortality rates almost mirroring each other …
Morphologic and molecular landscape of pancreatic cancer variants as the basis of new therapeutic strategies for precision oncology
C Bazzichetto, C Luchini, F Conciatori… - International journal of …, 2020 - mdpi.com
To date, pancreatic cancer is still one of the most lethal cancers in the world, mainly due to
the lack of early diagnosis and personalized treatment strategies. In this context, the …
the lack of early diagnosis and personalized treatment strategies. In this context, the …
T-cell receptor repertoire sequencing and its applications: focus on infectious diseases and cancer
The immune system is a dynamic feature of each individual and a footprint of our unique
internal and external exposures. Indeed, the type and level of exposure to physical and …
internal and external exposures. Indeed, the type and level of exposure to physical and …
The role of the microbiome in pancreatic cancer
K Miyabayashi, H Ijichi, M Fujishiro - Cancers, 2022 - mdpi.com
Simple Summary Pancreatic cancer is deadly cancer characterized by dense stroma
creating an immunosuppressive tumor microenvironment. Accumulating evidences indicate …
creating an immunosuppressive tumor microenvironment. Accumulating evidences indicate …
How should we test for Lynch syndrome? A review of current guidelines and future strategies
R Gallon, P Gawthorpe, RL Phelps, C Hayes… - Cancers, 2021 - mdpi.com
Simple Summary Carriers of Lynch syndrome (LS) have an increased risk for several types
of tumour, in particular bowel and uterine cancers. LS is caused by inheritance of a faulty …
of tumour, in particular bowel and uterine cancers. LS is caused by inheritance of a faulty …